Overview

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Phase 3 randomized, double-blind, placebo- and active comparator-controlled study of TLC599.
Phase:
Phase 3
Details
Lead Sponsor:
Taiwan Liposome Company
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate